EE03426B1 - Risperidooni vesilahuselised ravimvormid - Google Patents

Risperidooni vesilahuselised ravimvormid

Info

Publication number
EE03426B1
EE03426B1 EE9700009A EE9700009A EE03426B1 EE 03426 B1 EE03426 B1 EE 03426B1 EE 9700009 A EE9700009 A EE 9700009A EE 9700009 A EE9700009 A EE 9700009A EE 03426 B1 EE03426 B1 EE 03426B1
Authority
EE
Estonia
Prior art keywords
risperidone
aqueous formulations
formulations
aqueous
Prior art date
Application number
EE9700009A
Other languages
English (en)
Other versions
EE9700009A (et
Inventor
Karel Jozef Fran�ois Marc
Maria Albert Carlo Dries Willy
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26955530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03426(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE9700009A publication Critical patent/EE9700009A/et
Publication of EE03426B1 publication Critical patent/EE03426B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EE9700009A 1994-07-11 1995-07-04 Risperidooni vesilahuselised ravimvormid EE03426B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/272,462 US5453425A (en) 1994-07-11 1994-07-11 Risperidone oral formulation
US08/429,435 US5616587A (en) 1994-07-11 1995-04-26 Aqueous risperidone formulations
PCT/EP1995/002615 WO1996001652A1 (en) 1994-07-11 1995-07-04 Aqueous risperidone formulations

Publications (2)

Publication Number Publication Date
EE9700009A EE9700009A (et) 1997-08-15
EE03426B1 true EE03426B1 (et) 2001-06-15

Family

ID=26955530

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700009A EE03426B1 (et) 1994-07-11 1995-07-04 Risperidooni vesilahuselised ravimvormid

Country Status (36)

Country Link
US (3) US5453425A (et)
EP (1) EP0769965B1 (et)
JP (1) JP2872412B2 (et)
KR (1) KR100212942B1 (et)
CN (1) CN1148226C (et)
AP (1) AP774A (et)
AT (1) ATE206931T1 (et)
AU (1) AU684193B2 (et)
BG (1) BG63070B1 (et)
BR (1) BR9508253A (et)
CA (1) CA2194564C (et)
CY (1) CY2268B1 (et)
CZ (1) CZ285204B6 (et)
DE (1) DE69523313T2 (et)
DK (1) DK0769965T3 (et)
EE (1) EE03426B1 (et)
ES (1) ES2165918T3 (et)
FI (1) FI116510B (et)
HR (1) HRP950397B1 (et)
HU (1) HU222352B1 (et)
IL (1) IL114525A (et)
MX (1) MX9700374A (et)
MY (1) MY114389A (et)
NO (1) NO320366B1 (et)
NZ (1) NZ289432A (et)
PH (1) PH31626A (et)
PL (1) PL179972B1 (et)
PT (1) PT769965E (et)
RO (1) RO116778B1 (et)
RU (1) RU2161965C2 (et)
SI (1) SI9500220B (et)
SK (1) SK282159B6 (et)
TR (1) TR199500778A1 (et)
TW (1) TW420615B (et)
WO (1) WO1996001652A1 (et)
ZA (1) ZA955720B (et)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE288270T1 (de) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
SE0103211D0 (sv) * 2001-09-27 2001-09-27 Pharmacia Ab New formulations and use thereof
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
EP1534288A1 (en) * 2002-08-23 2005-06-01 Ranbaxy Laboratories, Ltd. Stable aqueous solutions of risperidone and methods for their preparation
EP1615924A1 (en) * 2003-04-22 2006-01-18 Synthon B.V. Water soluble salts of risperidone
PE20050285A1 (es) 2003-06-24 2005-06-09 Novartis Ag Composicion farmaceutica que comprende analogos ciclicos de somatostatina
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
ES2245891B1 (es) * 2004-07-09 2006-11-16 Clinmet S.L. "metodo para la obtencion de un excipiente universal para la administracion oral de principios activos farmaceuticos y composiciones de excipientes resultantes del metodo".
WO2006129160A2 (en) * 2005-06-01 2006-12-07 Aurobindo Pharma Limited Stable aqueous oral solution of risperidone
DE602006005423D1 (de) * 2005-06-29 2009-04-16 Verisfield Uk Ltd Pharmazeutische Zusammensetzungen von Risperidon in wässriger Lösung
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
JP4922657B2 (ja) * 2006-05-09 2012-04-25 高田製薬株式会社 リスペリドン経口用液剤
WO2007138462A2 (en) * 2006-06-01 2007-12-06 Wockhardt Ltd Aqueous oral formulations of risperidone
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
US7776866B2 (en) * 2007-09-15 2010-08-17 Protia, Llc Deuterium-enriched risperidone
CN101932327A (zh) * 2007-12-19 2010-12-29 詹森药业有限公司 与长效注射用帕潘立酮酯相关的给药方案
ES2731228T3 (es) 2009-01-20 2019-11-14 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Acido benzoico o sales del mismo para mejorar la actividad de un producto farmacéutico
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
AU2012321345B2 (en) * 2011-10-03 2016-03-17 The University Of Utah Research Foundation Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
NZ731309A (en) 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens
KR102403048B1 (ko) 2016-06-13 2022-05-26 신유알엑스 인터내셔널 (타이완) 코포레이션 벤조산나트륨의 공-결정 및 그의 용도
TWI736635B (zh) 2016-06-13 2021-08-21 心悅生醫股份有限公司 苯甲酸鋰之共晶及其用途
KR20190066608A (ko) * 2016-09-23 2019-06-13 델포어, 인코포레이티드 소분자 치료제 화합물 조성물
RU2646812C1 (ru) * 2016-10-24 2018-03-07 Общество с ограниченной ответственностью "Трейдсервис" Жидкая лекарственная форма рисперидона и способ ее получения
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN107260662A (zh) * 2017-06-21 2017-10-20 南京正科医药股份有限公司 一种利培酮口服溶液及其制备方法
CN107441037A (zh) * 2017-08-16 2017-12-08 南京正科医药股份有限公司 一种利培酮口服溶液
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
JP2021515038A (ja) * 2018-02-27 2021-06-17 デルポー・インコーポレイテッドＤｅｌｐｏｒ， Ｉｎｃ． 小分子治療剤化合物のための組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337261A (en) * 1980-07-28 1982-06-29 Hoechst-Roussel Pharmaceuticals Inc. (1,2-Benzisoxazol)phenoxyacetic acids as diuretics
US4793992A (en) * 1987-03-25 1988-12-27 Redken Laboratories, Inc. Hair treatment composition
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
FR2641278B1 (fr) * 1989-01-05 1991-03-22 Lipha Piperidines, procedes de preparation et medicaments les contenant
DK203990D0 (da) * 1990-08-24 1990-08-24 Novo Nordisk As Piperazinylderivater
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
FR2796273B1 (fr) * 1999-07-15 2003-09-12 Oreal Composition a phase grasse liquide gelifiee par un polyamide a groupements ester terminaux

Also Published As

Publication number Publication date
SK2297A3 (en) 1997-09-10
AU2927595A (en) 1996-02-09
CN1155247A (zh) 1997-07-23
BG101106A (en) 1997-08-29
HUT76826A (en) 1997-11-28
HU9700082D0 (en) 1997-02-28
NO970051D0 (no) 1997-01-07
AU684193B2 (en) 1997-12-04
PL179972B1 (pl) 2000-11-30
IL114525A (en) 1999-06-20
TR199500778A1 (tr) 1996-10-21
RU2161965C2 (ru) 2001-01-20
CA2194564C (en) 1997-12-16
DE69523313D1 (de) 2001-11-22
USRE39181E1 (en) 2006-07-11
JPH09511751A (ja) 1997-11-25
HRP950397B1 (en) 2002-04-30
AP9700910A0 (en) 1997-01-31
ATE206931T1 (de) 2001-11-15
US5616587A (en) 1997-04-01
CZ285204B6 (cs) 1999-06-16
US5453425A (en) 1995-09-26
SK282159B6 (sk) 2001-11-06
PL318132A1 (en) 1997-05-12
EE9700009A (et) 1997-08-15
SI9500220B (sl) 2004-12-31
CY2268B1 (en) 2003-07-04
HRP950397A2 (en) 1997-10-31
CZ2797A3 (en) 1997-07-16
NO970051L (no) 1997-01-07
TW420615B (en) 2001-02-01
RO116778B1 (ro) 2001-06-29
SI9500220A (en) 1996-02-29
KR970704472A (ko) 1997-09-06
NZ289432A (en) 1998-05-27
BG63070B1 (bg) 2001-03-30
DE69523313T2 (de) 2002-06-27
CN1148226C (zh) 2004-05-05
MY114389A (en) 2002-10-31
KR100212942B1 (ko) 1999-08-02
FI970109L (fi) 1997-01-10
PT769965E (pt) 2002-04-29
ES2165918T3 (es) 2002-04-01
ZA955720B (en) 1997-01-10
PH31626A (en) 1999-01-12
JP2872412B2 (ja) 1999-03-17
FI970109A0 (fi) 1997-01-10
HK1010691A1 (en) 1999-06-25
BR9508253A (pt) 1997-12-23
EP0769965A1 (en) 1997-05-02
EP0769965B1 (en) 2001-10-17
FI116510B (fi) 2005-12-15
DK0769965T3 (da) 2002-02-04
NO320366B1 (no) 2005-11-28
WO1996001652A1 (en) 1996-01-25
AP774A (en) 1999-10-28
CA2194564A1 (en) 1996-01-25
IL114525A0 (en) 1995-11-27
HU222352B1 (hu) 2003-06-28
MX9700374A (es) 1997-04-30

Similar Documents

Publication Publication Date Title
DK0769965T3 (da) Vandige risperidonformuleringer
FI20055562L (fi) Alfa-interferonin stabiilit vesiliuosformulaatit
BR9510256A (pt) Derivados de ácido 3-aril-tetrônico
NO986208D0 (no) Vandige peptidformuleringer
FI970240A7 (fi) Vaahtoamaan kykenevä vesipitoinen koostumus
FI950910A0 (fi) Rasvahappojohdannaiset
IS2325B (is) Örgerðar samsetningar epleróns
DE69518331D1 (de) Orale zubereitungen
DE69732787D1 (de) Wässrige körperreinigungsmittelzusammensetzung
EE9500059A (et) Asendatud 4-fenüül-6-aminonikotiinhappe derivaatide kasutamine ravimitena
FI950909L (fi) Rasvahappojohdannaisia
NO306350B1 (no) Vandig rengjöringspreparat
FI953887A7 (fi) Kefaklorin farmaseuttisia formulaatioita
IT1276799B1 (it) Formulazioni di f-silicone
DE69619640D1 (de) Wässrige Austrichstoffe
ITMI20011389A0 (it) Formulazioni farmaceutiche acquose di cromoglicato sodico
DE69432149D1 (de) Orale Zubereitungen
FI934687L (fi) Vattenhaltiga komposition
FI953580A0 (fi) Asyklovirin valmistus
SE9404467D0 (sv) Drug formulations
ITRM920116A0 (it) Formulazioni liposomiche di piroxicam.

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231